Navigation Links
Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Date:8/19/2007

with Reclast therapy. In the Pivotal Fracture Trial an increased number of cases of serious atrial fibrillation were observed in women given Reclast compared to those on placebo (1.3% vs. 0.4% respectively)(2). The timing of these events suggest that they were not related to the acute infusion. This finding has not been observed in other zoledronic acid clinical studies and in post-marketing experience from more than 1.5 million patients treated with Zometa.

All patients with Paget's disease should receive 1500 mg of calcium in divided doses and 800 IU of vitamin D daily, particularly in the two weeks following Reclast administration. It is recommended that patients with postmenopausal osteoporosis take calcium and vitamin D supplements, if dietary intake is not sufficient.

For more information about Reclast, visit http://www.reclast.com or call 866-RECLAST (866-732-5278).

Disclaimer

The foregoing press release contains forward-looking statements that can be identified by the use of forward-looking terminology such as "potential", "anticipated", "generally follows", "expected", "hope", "will", or similar expressions, or by express or implied discussions regarding potential future regulatory approvals of Reclast/Aclasta, or potential future sales of Reclast/Aclasta. Such forward-looking statements reflect the current views of Novartis regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Reclast/Aclasta will be approved for sale, or for any additional indications or labeling in any market, or that Reclast/Aclasta will reach any particular level of sales. In particular, management's expectations regarding Reclast/Aclasta could be affected by, among other things, unexpected reg
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation

Copyright©2007 PR Newswire.

1

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Lucigen receives $750K grant to boost biofuel yields
3. Medical College receives $1.4M cancer grant
4. Wisconsin biotech firm receives $107K NIH grant
5. InvivoSciences receives NIH grant for heart technology
6. Medical College receives $11 million grant to study high blood pressure
7. Madison business receives $115,000 of new state biofuels funding
8. Superior receives funds for technical training
9. UWM receives state funding for plastics research
10. GEs Centricity EHR receives federal certification
11. WHIE receives state eHealth Initiative contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... and TEL AVIV, Israel , May 24, ... "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, ... President and Chief Executive Officer, and Craig Shore ... the Benchmark Company, LLC One-on-One Investor Conference on Thursday May ... Milwaukee, WI. The format ...
(Date:5/24/2013)... May 24, 2013 Senomyx , Inc. ... taste science technologies to discover, develop, and commercialize novel ... , Ph.D., the Company,s Vice President, Biology and ... Relations & Corporate Communications, will present an overview of ... 10:25 a.m. Eastern Time (7:25 a.m. Pacific Time) during ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 This ... survey on kinase profiling carried out in May ... of the breakdown of the responses for each ... future (2015). It also highlights some interesting differences, ... groupings. Two bottom-up models were developed to estimate ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Many factors ... and uptake or efflux transporters at the blood-tissue barrier. ... related to unbound fractions in the tissue rather than ... these disposition challenges is required to guide lead optimization, ... identify any species-dependent variables that may impact the likely ...
Breaking Biology Technology:InspireMD To Participate In Benchmark Investor Conference On May 30th 2InspireMD To Participate In Benchmark Investor Conference On May 30th 3InspireMD To Participate In Benchmark Investor Conference On May 30th 4SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 2Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 3Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 4DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2
... Market, According to a ... New Report from Decision Resources, WALTHAM, Mass., Oct. 17 ... that Merck,will obtain blockbuster antidiabetic drug sales in the type 2 ... will see rapid uptake as a second-and third-line agent in type ...
... Kyphon Inc.,(Nasdaq: KYPH ) announced today that its ... Inc. (NYSE: MDT ) at a special,meeting of ... 26, 2007, Kyphon entered into a,definitive merger agreement with ... the outstanding shares of Kyphon common stock for,$71.00 per ...
... LAWRENCE, Mass., Oct. 16 NxStage Medical,Inc. (Nasdaq: ... plans to release its financial results for the third,quarter ... of the,financial markets. NxStage will also host a ... 2007 to discuss its third quarter 2007 financial results. ...
Cached Biology Technology:Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011 2Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011 3Kyphon Stockholders Approve Merger with Medtronic 2NxStage(R) Medical to Report Third Quarter 2007 Financial Results on Friday, November 2nd 2
(Date:5/24/2013)... in one French Quarter neighborhood of New Orleans to ... Annette Hurley, PhD, Assistant Professor of Audiology at LSU ... third-year LSUHSC doctor of audiology student, recommend that people ... Their case study is published online in the current ... "An important part of an audiologist,s practice is aiding ...
(Date:5/24/2013)... the search for medication against Alzheimer,s disease, scientists have focused ... down Amyloid beta (A-beta). After all, it is the accumulation ... of Alzheimer,s patients. Starting point for the formation of A-beta ... the first to unravel the function of APPL the ... fruit flies. , Alessia Soldano (VIB/KU Leuven): "We have ...
(Date:5/24/2013)... A conference of 500 leading water scientists from around ... major reforms, "in the short span of one or ... on Earth will be living under the handicap of ... resource for which there is no substitute. This handicap ... , The scientists bluntly pointed to chronic underlying problems ...
Breaking Biology News(10 mins):Please do try this at home 2A new strategy required in the search for Alzheimer's drugs? 2A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 2A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 3A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 4
... cells decide whether to have sex with each other within ... in Nature . One of the authors of the ... how yeast cells decide to mate could be helpful for ... Yeasts are single-celled microbes that scientists often use as ...
... The Wildlife Conservation Society announced the restoration of ... preserved plant specimensin a multi-partner effort that will ... inform decision-making regarding the future management and protection ... organized by the U.S. Agency for International Development ...
... Cancer Society estimates one man in six will get prostate ... cancer death in men. With a new partnership with Areva ... drug in stopping the growth of prostate cancer tumors. ... Dong, PhD, will test the efficacy of a new agent ...
Cached Biology News:You had me at hello: Frisky yeast know who to 'shmoo' after 2 minutes 2You had me at hello: Frisky yeast know who to 'shmoo' after 2 minutes 3Critical record of Afghanistan's natural heritage blooms again 2UC to test targeted treatment for prostate cancer 2
Mouse monoclonal [DJR3] to DcR1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
... most comprehensive, cost-effective solution to your ... unprecedented quality into both our products ... detection chemistries and antibodies that have ... It also includes our competitively priced ...
... RED Chromogen System consists of ... buffer. FAST RED reacts in ... to produce red staining with ... The FAST RED tablets ...
Mouse Cell Line Slides...
Biology Products: